Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-25
2009-10-27
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S015800, C514S016700, C514S017400
Reexamination Certificate
active
07608589
ABSTRACT:
Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.
REFERENCES:
patent: 5614414 (1997-03-01), Ryan et al.
patent: 6552007 (2003-04-01), Chen et al.
patent: 6696072 (2004-02-01), Podolski
patent: 7358044 (2008-04-01), Thacker et al.
patent: 1319667 (2003-06-01), None
Morgan et al., Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases, 1989, Annual Reports in Medicinal Chemistry 24: 243-252.
Ripka et al., Peptidomimetic design, 1998, Current Opinion in Chemical Biology 2:441-452.
Hruby et al., Synthesis of oligopeptide and peptidomimetic libraries, 1997, Current Opinion in Chemical Biology 1:114-119.
Hruby et al., Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads, 2000, Current Medicinal Chemistry 7:945-970.
Hart et al., Susceptibility to hydrophobic molecules and phospholipid composition inPasteruella multocidaandActinobacillus lignieresii, 1988, Antimicrob. Agents Chemother. 32:1354-1359.
Fujino et al., Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion, 2003, PNAS 100(1):229-234.
http://en.wikipedia.org/wiki/Low-density—lipoprotein, date Jun. 9, 2004, 1 page.
Remington's Pharmaceutical Sciences, Mack Publishing, Co., Easton, PA (TOC), date May 10, 2005, 13 pages.
Darnell et al., Variability of cell surface hydrophobicity amongPasteruella multocidasomatic serotype andActinobacillus lignieresiistrains, 1987, J. Clin. Microbiol. 25:67-71.
Hancock, Peptide antibiotics,1997, Lancet 349:418-422.
Tizard, Veterinary Immunology: An Introduction, 5thed., Philadelphia, PA, W.B. Saunders Company, 1996 (TOC).
Zinkl, The leukocytes, 1981, Vet. Clin. North Am. Small Anim. Pract. 11:237-263.
Latimer et al., Clinical Interpretation of leukocyte responses, 1989, Vet. Clin. North Am: Small Anim. Pract. 19:637-668.
Maxwell, Avian blood leukocyte responses to stress, 1993, Worlds Polult. Sci. J. 49:34-43.
Lucas et al., Atlas of avian hematology, 1961, United States Department of Agriculture, Agriculture Monograph 25, Washington, D.C. (TOC).
Kaisho et al., Toll-Like Receptors as Adjuvant Receptors, 2002, Biochim. Biophys. Acta 1589:1-13.
Medzhitov, Toll-Like Receptors and Innate Immunity, 2001, Nat. Rev. Immunol 1:135-145.
Hallman et al., Toll-like Receptors as Sensors of Pathogens, 2001, Pediatr. Res. 50:315-321.
Poquet et al., Expansion of Vγ9Vδ2 T Cells is Triggered byFrancisella tularensis-Derived Phosphoantigens in Tularemia but Not after Tularemia Vaccination, 1998, Infect. lmmun. 66:2107-2114.
Carding et al., γδ Cells: Functional Plasticity and Heterogeneity, 2002, Nat. Rev. lmmunol. 2:336-345.
Ladel et al., Control of Natural Killer Cell-Mediated Innate Resistance against the Intracellular Pathogen Listeria monocytogenes by γ/δ T Lymphocytes, 1996, Infect. Immun. 64(5):1744-1749.
Chen et al., Adaptive immune response of Vγ2Vδ2 T cells: a new paradigm, 2003, Trends in Immunology 24:213-219.
Zuany-Amorim et al., Toll-Like Receptors as Potential Therapeutic Targets for Multiple Diseases, 2002, Nat. Rev. Drug Discov. 1:797-807.
Takeuchi et al., Toll-like receptors; their physiological role and signal transduction system, 2001, Int. lmmunopharmacol. 1:625-635.
Akira et al., Toll-like receptors: critical proteins linking innate and acquired immunity, 2001, Nat. lmmunol. 2:675-680.
Werling et al., Toll-like receptors linking innate and adaptive immune responses, 2003, Vet. lmmunol. Immunopathol. 91:1-12.
Braun, Covalent Lipoprotein from the Outer Membrane ofEscherichia coli, 1975, Biochem. Biophys. Acta 415:335-337.
Okusawa, 2004, Infection and Immunity 72:1657-1665.
Bessler et al., Induction of Lymphocyte Proliferation and membrane Changes by Lipopeptide Derivatives of the Lipoprotein from the Outer Membrane ofEscherichia coli, 1997, Z. Immun.-Forsch. 15:11-22.
Sumida et al., Predominant Expansion of Vγ9/Vδ2 T Cells in a Tularemia Patient, 1992, Infect. Immunol. 60(6):2554-2558.
Hara et al., Predominant Activation and Expansion of Vγ9-bearing γδT Cells in Vivo as well as In Vitro in Salmonella Infection, 1992, J. Clin. Invest. 90:204-210.
Modlin et al. Lymphocytes bearing antigen-specific γδ T-cell receptors accumulate in human infectious disease lesions, 1989, Nature, 339:544-548.
Jouen-Beades et al., In Vivo and In Vitro Activation and expansion of γδ T Cells during Listeria monocytogenes Infection in Humans, 1997, Infect. Immun. 65(10):4267-4272.
Russo et al., Antigen-Reactive γδ T Cells in Human Leishmaniasis, 1993, J. Immunol. 151(7):3712-3718.
Ho et al., Increased γδ cells in acutePlasmodium falciparummalaria, 1990, Immunol. Lett. 25:139-141.
Hoft et al., Bacille Calmette-Guerin Vaccination enhances Human γδ T Cell Responsiveness to Mycobacteria Suggestive of a Memory-Like Phenotype, 1998, J. lmmunol. 161:1045-1054.
Mohr et al., Radical-Mediated Oxidation of Isolated Human Very-Low-Density Lipoprotein, 1994, Arterioscler. Thromb. 14:1186-1192.
Aceto, Esq. Joseph F.
Cordero Garcia Marcela M
Therimunex Pharmaceuticals, Inc.
Tsang Cecilia
Wilcox, Esq. James L.
LandOfFree
Peptidyl diacylglycerides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidyl diacylglycerides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidyl diacylglycerides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130815